Form 4: Lenz Therapeutics Executive Granted Stock Options
SEC Form 4 Filing
Shawn Olsson, Chief Commercial Officer of Lenz Therapeutics, was granted stock options to purchase 80,100 shares of common stock.
Summary
- Shawn Olsson, the Chief Commercial Officer of Lenz Therapeutics, was granted stock options on January 9, 2025.
- The options allow Olsson to purchase 80,100 shares of Lenz Therapeutics common stock at an exercise price of $26.34 per share.
- The options vest over time, with 25% vesting on the one-year anniversary of the Vesting Commencement Date (January 9, 2025), and the remaining shares vesting monthly thereafter over 36 months.
- Olsson also signed a Power of Attorney, effective January 13, 2025, authorizing certain individuals to act on his behalf in matters related to SEC filings.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future prospects. The sentiment is neutral to positive.
Positives
- The granting of stock options aligns the executive's interests with those of the shareholders.
- The vesting schedule incentivizes long-term commitment from the executive.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance, but the granting of stock options suggests an expectation of future value creation.
Industry Context
Stock option grants are a common practice in the biotechnology industry to attract and retain key executives and align their interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotech industries.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options to incentivize their executives.
- The vesting schedule and exercise price are typical for such grants, designed to reward long-term performance and commitment.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it aligns executive interests with company performance.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/09/2025 | Date of earliest transaction (grant date of stock options) and Vesting Commencement Date |
| 01/13/2025 | Date of Power of Attorney execution |
| 01/08/2035 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.